TPWA
RYTM icon

Twin Peaks Wealth Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6
Closed -$522 – 1804
2026
Q1 		$522 Buy
+6
New +$583 ﹤0.01% 2022
2025
Q3 		– Sell
-5
Closed -$482 – 1711
2025
Q2 		$482 Buy
+5
New +$306 ﹤0.01% 1925

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Twin Peaks Wealth Advisors's RYTM Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2026, closing a stake of 6 shares — an estimated $522 sold.

Twin Peaks Wealth Advisors first reported a position in RYTM in Q2 2025 and held it in 2 quarters. The position peaked at $522 in Q1 2026. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Rhythm Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 6 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $522.
  • Twin Peaks Wealth Advisors first reported a position in Rhythm Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's Rhythm Pharmaceuticals position peaked at $522 in Q1 2026.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.